Dr. John Cush RheumNow
6 years 10 months ago
FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers. https://t.co/L9lcHfosU1
Dr. John Cush RheumNow
6 years 10 months ago
The RheumNow Podcast is up - The Elusive Hand OA Problem (12.13.19) Watch it here>> https://t.co/l75xB48JqW or listen to the podcast here >> https://t.co/hLChtsUSdu
Dr. John Cush RheumNow
6 years 10 months ago
Great Full Text, Full Read review of obstructive sleep apnea in 12/3/19 Annals of Internal Medicine
Mild OSA: AHI or REI ≥5 but <15 events/h
Moderate OSA: AHI or REI ≥15 but <30 events/h
Severe OSA: AHI or REI ≥30 events/h https://t.co/nwNwejhLCn
Dr. John Cush RheumNow
6 years 10 months ago
YET another drug fails in erosive hand OA (EHOA). A phase II trial of an IL-1 inhibitor (lutikizumab) vs PBO given to 110 EHOA pts shows not differences in pain outcomes, despite biologic changes in CRP, IL1, neutrophils in those on the IL-1 inhibitor. https://t.co/i2N4vs0Sjb
Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.
This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.
There were 9 predictors of an inpatient gout flare:
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Dr. John Cush RheumNow
6 years 10 months ago
More than half of all US physicians recommend complementary health approaches (CHAs) to their pts - Most rec: massage therapy 30%, chiropractic/osteopathic manipulation 27%, herbs/supplements 26%, yoga 26% and acupuncture 22%. https://t.co/eyiU3LbNLN
Dr. John Cush RheumNow
6 years 10 months ago
Nurses Health Study - 284 incident #RA cases compared to 849 controls showing Asthma (not assoc w/ RA) but was strongly assoc w/ ACPA in blood prior to RA Dx (OR 3.6), independent of smoking. Chronic mucosal inflammation may lead to ACPA & RA https://t.co/h9dEPd7oYu
Lancet reports that prednisolone 10 mg daily for 6 weeks can effectively control the pain of hand osteoarthritis (OA), according to results from the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study.
This was a double-blind, randomized, placebo-controlled trial aimed to assess the short-term effects of prednisolone in painful hand OA and synovial inflammation. Patients were required to have hand OA and signs of inflammation in their distal
Patients with systemic sclerosis (SSc) who have persistent inflammation -- characterized by consistently elevated levels of C-reactive protein (CRP) -- have more severe disease and worse outcomes, a retrospective study confirmed.
Dr. John Cush RheumNow
6 years 10 months ago
Abarca, a pharmacy benefits manager, reports Amgen has agreed to give its health insurer clients an additional discount (amount$$??) on Enbrel, if patients discontinue taking it after three months - to help health insurers save costs if pts d/c Enbrel https://t.co/uhyAiJTcAj
Dr. John Cush RheumNow
6 years 10 months ago
American College of Cardiology review of Colchicine (biology, hx, pharmacology, use) in the treatment of pericardial disease (acute/chronic/recurrent pericarditis, pericardial effusion, Post-cardiac Injury Syndrome). Full read review available. https://t.co/8Yz0J1KCyV
IgG4-related disease (IgG4-RD) is a relatively new disorder since 2003, and may present as a diagnostic challenge as it can cause fibroinflammatory pathology in nearly any organ.
Dr. John Cush RheumNow
6 years 10 months ago
J Rheum metanalysis of 12 studies & 3,234 SLE pt vs 288,336 control subjects shows a significant association between SLE occurrence and current-smoker (not former) (OR 1.54) https://t.co/shL8LT6Kbj
